Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) is an investigational allogeneic cell therapy developed by Hebei Medical University for the treatment of systemic lupus erythematosus (SLE). This biologic modality involves the intravenous administration of mesenchymal stem cells harvested from umbilical cord tissue. The therapeutic mechanism is centered on immunomodulation and metabolic reprogramming; specifically, the cells influence the glucose metabolism pathways of CD4+ T cells to suppress the overactive immune response characteristic of SLE. Clinical research conducted by Hebei Medical University has evaluated the safety and efficacy of these cells in patients with active and refractory disease, often as an adjunct to conventional immunosuppressive therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (Hebei Medical University).